Loading…
Apogee Therapeutics, Inc. is projected to rise to $100.16 by 2027, a +29% move from its current price of $77.75. APGE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $75.92 | $77.75 | $79.61 | 0.00% |
| May 30 | $75.18 | $77.74 | $80.39 | -0.01% |
| May 31 | $74.61 | $77.74 | $81.00 | -0.01% |
| Jun 1 | $74.14 | $77.74 | $81.51 | -0.02% |
| Jun 2 | $73.72 | $77.73 | $81.96 | -0.02% |
| Jun 3 | $73.34 | $77.73 | $82.38 | -0.03% |
| Jun 4 | $73.00 | $77.72 | $82.76 | -0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $73.00 | $77.72 | $82.76 | -0.03% |
| Week 2 | $71.10 | $77.70 | $84.91 | -0.07% |
| Week 3 | $69.68 | $77.67 | $86.59 | -0.10% |
| Week 4 | $68.49 | $77.65 | $88.03 | -0.13% |
| Week 5 | $67.46 | $77.62 | $89.31 | -0.17% |
| Week 6 | $66.54 | $77.59 | $90.48 | -0.20% |
| Week 7 | $65.71 | $77.57 | $91.57 | -0.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Apogee Therapeutics, Inc. is a clinical stage biotechnology company that develops novel biologics for inflammatory and immunology indications in the United States. Its programs include Zumilokibart (APG777), a subcutaneous extended half-life monoclonal antibody for atopic dermatitis, which is in phase 2 clinical trials; and for asthma and eosinophilic esophagitis, which is in phase 1 clinical trial.
It also develops APG279 in phase 1 for atopic dermatitis; APG273 in phase 1 for asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases.
Apogee Therapeutics was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
APGE is the stock with a current price of $81.16 and a market capitalization of $6.12B. It is ranked 1202 by market capitalization among its peers.
The stock exhibits notable volatility, with annualized volatility of 40%. The 30-day technical picture shows bullish sentiment with a near-term range that supports a potential move higher in the period ahead. The 30-day range spans from $70.82 to $93.01.
Forecasts indicate a bullish price trajectory over the longer term, with the average forecast price rising across multiple years. The 2030 average is $162.50, the 2040 average is $363.50, and the 2050 average is $793.75, reflecting a sustained upside path over the coming years.
A major floor 20.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 18.6% above — a clean break opens room to run.
A major ceiling 24.8% above — clearing it would confirm fresh momentum.
Key APGE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APGE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $81.11 | Sell | $80.43 | Sell |
| MA 10 | $81.16 | Sell | $81.14 | Sell |
| MA 20 | $82.05 | Sell | $82.08 | Sell |
| MA 50 | $82.39 | Sell | $81.21 | Sell |
| MA 100 | $77.28 | Buy | $76.96 | Buy |
| MA 200 | $65.54 | Buy | $68.64 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.61 | Neutral |
| Stoch RSI (14) | 14.05 | Buy |
| CCI (20) | -186.25 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.41 | Sell |
| ROC (12) | -6.36 | Sell |
| Bollinger %B (20,2) | -0.06 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.09 | Sell |
| Awesome (5,34) | -3.58 | Sell |
| Ultimate (7,14,28) | 37.87 | Neutral |
| Momentum (10) | -5.18 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 81.30 | Sell |
| ADX (14) | 11.79 | Neutral |
| ATR (14) | 1.84 | Info |
The near-term picture is described as bullish, with RSI at 50 and a generally positive reading of market momentum.
Key moving averages are SMA50 at $82.03 and SMA200 at $65.10, suggesting near-term price support around the mid-to-high $70s and potential resistance near the $92.20 level. Support is indicated at $78.27, with resistance at $92.20. The 30-day range runs from $70.82 to $93.01, outlining a broad trading band for the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $62.13 | $77.75 | $104.93 | 0% | Neutral | |
| $80.45 | $100.16 | $131.47 | +29% | Bullish | |
| $96.41 | $122.85 | $166.43 | +58% | Bullish | |
| $106.65 | $138.55 | $192.47 | +78% | Bullish | |
| $115.56 | $152.72 | $216.71 | +96% | Bullish | |
| $114.98 | $154.34 | $223.16 | +99% | Bullish | |
| $122.53 | $166.89 | $245.39 | +115% | Bullish | |
| $139.39 | $192.45 | $287.34 | +148% | Bullish | |
| $150.96 | $211.13 | $319.71 | +172% | Bullish | |
| $175.80 | $248.92 | $381.93 | +220% | Bullish | |
| $215.69 | $322.88 | $523.60 | +315% | Bullish | |
| $429.25 | $706.21 | $1,242.42 | +808% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $62.13 | $77.75 | $91.42 | +0.00% |
| June 2026 | $67.00 | $78.46 | $93.89 | +0.91% |
| July 2026 | $65.63 | $77.41 | $93.74 | -1.33% |
| August 2026 | $66.85 | $79.30 | $96.89 | +2.44% |
| September 2026 | $68.94 | $82.17 | $101.14 | +3.61% |
| October 2026 | $68.37 | $81.84 | $101.41 | -0.40% |
| November 2026 | $67.65 | $81.29 | $101.32 | -0.67% |
| December 2026 | $69.42 | $83.72 | $104.93 | +2.99% |
Click any year to see its month-by-month APGE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The APGE price prediction for 2026 points to an average of $77.75 (low $62.13, high $104.93) — a potential gain of 0% on today's $77.75. Price action looks broadly range-bound.
In 2027, APGE is projected to trade between $80.45 and $131.47, averaging $100.16 — a potential gain of +29% from today's $77.75. That is up +29% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Apogee Therapeutics, Inc.'s 2028 outlook centres on $122.85, within a $96.41 to $166.43 range. That is up +23% on the projected 2027 average. That marks a +58% change versus current levels. Momentum favours further upside here.
By 2029, APGE could reach as high as $192.47, with a base case around $138.55 and support toward $106.65 — roughly +78% from $77.75. Buyers look set to stay in control over this stretch.
Expect APGE to range from $115.56 to $216.71 through 2030. The $152.72 average target implies a +96% move from current prices. That is up +10% on the projected 2029 average. Momentum favours further upside here.
The APGE price prediction for 2031 points to an average of $154.34 (low $114.98, high $223.16) — a potential gain of +99% on today's $77.75. Buyers look set to stay in control over this stretch.
In 2032, APGE is projected to trade between $122.53 and $245.39, averaging $166.89 — a potential gain of +115% from today's $77.75. That is up +8% on the projected 2031 average. Momentum favours further upside here.
Apogee Therapeutics, Inc.'s 2033 outlook centres on $192.45, within a $139.39 to $287.34 range. That is up +15% on the projected 2032 average. That marks a +148% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, APGE could reach as high as $319.71, with a base case around $211.13 and support toward $150.96 — roughly +172% from $77.75. Momentum favours further upside here.
Expect APGE to range from $175.80 to $381.93 through 2035. The $248.92 average target implies a +220% move from current prices. That is up +18% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The APGE price prediction for 2040 points to an average of $322.88 (low $215.69, high $523.60) — a potential gain of +315% on today's $77.75. Momentum favours further upside here.
In 2050, APGE is projected to trade between $429.25 and $1,242.42, averaging $706.21 — a potential gain of +808% from today's $77.75. That is up +119% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in APGE today (≈ 12.861736 APGE) could be worth
$9,083.06
+$8,083.06 (+808%) by 2050 · US Dollar
Based on the average projected APGE price of $706.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APGEwould be worth at today's price.
$1,000 invested in APGE on May 27, 2025 (≈ 27.114967 APGE) would be worth
$2,108.19
+$1,108.19 (+110.8%) today · 2.11× · US Dollar
Based on a APGE entry price of $36.88 vs. today's $77.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $81.39 | $955.28 | -4.5% |
| 1 month ago | $86.47 | $899.16 | -10.1% |
| 3 months ago | $69.09 | $1,125.34 | +12.5% |
| 6 months ago | $71.97 | $1,080.31 | +8.0% |
| 1 year ago | $36.88 | $2,108.19 | +110.8% |
| All time (2.9y) ago | $21.23 | $3,662.27 | +266.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APGE forecast.
Our base-case forecast reaches $160.00 around 2032.
Implied market cap at $160.00: $9.9B
The multi-year forecast shows a clear upward trajectory starting from 2027 onward. The 2026 forecast sits at an average of $81.16 with a neutral sentiment and a min of $62.13 and a max of $109.90. By 2027 the average climbs to $105.83 with a bullish sentiment and a 30.4% ROI, and it advances further to $130.60 in 2028 (60.9% ROI) and $147.90 in 2029 (82.2% ROI).
In 2030 the average is projected at $162.50 with a 100.2% ROI and a max of $225.25, maintaining a bullish outlook. The forecast continues to rise in subsequent years, with 2031 at $167.40 (106.3% ROI), 2032 at $182.81 (125.3% ROI), and 2033 at $209.84 (158.6% ROI). By 2034 the average is $232.63 (186.6% ROI) and 2035 at $273.24 (236.7% ROI).
The long horizon shows substantial upside, with 2040 average $363.50 (347.9% ROI) and 2050 average $793.75 (878% ROI), both reflecting bullish sentiment. These figures illustrate an elevated price path over time, though they are estimates and not guarantees.
Tap a question to reveal the answer.
The forecasted average price for 2030 is $162.50 with an estimated ROI of 100.2%.
Forecasts show bullish sentiment in 2027 onward and rising averages to 162.50 by 2030, 363.50 by 2040, and 793.75 by 2050, with ROIs of 100.2%, 347.9%, and 878% respectively. These are estimates and not guaranteed.
Yes—the 2030 forecast shows a max of $225.25.
Current price is $81.16 and market cap is $6.12B.
The 30-day range is from $70.82 to $93.01.
Apogee Therapeutics, Inc. Community Discussion
0Share your Apogee Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.